Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.
FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by Anti-Human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/mL. The EC50 for Anti-Human PCSK9 antibody is 6.816-12.67 μg/mL.
Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Human LDL R, His Tag (Cat. No. LDR-H5224) with an affinity constant of 12.7 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Inclisiran sodium | ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839 | Approved | Alnylam Pharmaceuticals Inc | Leqvio, 乐可为 | EU | Dyslipidemias; Hypercholesterolemia | Novartis Europharm Ltd | 2020-12-09 | Acute Coronary Syndrome; Diabetes Mellitus; Hyperlipidemias; Hyperlipoproteinemia Type II; Cardiovascular Diseases; Dyslipidemias; Coronary Disease; Heterozygous familial hypercholesterolemia; Hypolipoproteinemias; Stroke; Homozygous familial hypercholesterolemia; Kidney Diseases; Coronary Artery Disease; Hypercholesterolemia; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Myocardial Infarction; Atherosclerosis; Plaque, Atherosclerotic | Details |
| Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | EU | Dyslipidemias; Hypercholesterolemia | Amgen Europe Bv | 2015-07-17 | Acute Coronary Syndrome; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Hyperlipoproteinemia Type II; Hyperlipidemias; Glioma; Rejection in heart transplantation; Cardiovascular Diseases; Coronary Disease; Heterozygous familial hypercholesterolemia; Dyslipidemias; Stroke; HIV Infections; Sepsis; Glioblastoma; Coronary Artery Disease; Hypercholesterolemia; Heart Failure; Atherosclerosis; Myocardial Infarction; Diabetes Mellitus, Type 2; ST Elevation Myocardial Infarction; Homozygous familial hypercholesterolemia | Details |
| Tafolecimab | IBI-306 | Approved | Innovent Biologics(Suzhou) Co Ltd | 信必乐 | Mainland China | Dyslipidemias; Hypercholesterolemia | Innovent Biologics(Suzhou) Co Ltd | 2023-08-15 | Homozygous familial hypercholesterolemia; Drug-Related Side Effects and Adverse Reactions; Hypercholesterolemia; Dyslipidemias; Heterozygous familial hypercholesterolemia | Details |
| Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Sanofi | 波立达, Praluent | United States | Hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2015-07-24 | Stroke; Hyperlipidemias; Drinking Behavior; Cardiovascular Diseases; Coronary Disease; Vascular Diseases; Heterozygous familial hypercholesterolemia; Dyslipidemias; Acute Coronary Syndrome; Hemorrhage; Intracranial Arteriosclerosis; Angina Pectoris; Shock, Septic; Hypercholesterolemia; Sepsis; ST Elevation Myocardial Infarction; Diabetes Mellitus, Type 2; Atherosclerosis; Myocardial Infarction; Liver Diseases, Alcoholic; HIV Infections; Plaque, Atherosclerotic; Homozygous familial hypercholesterolemia | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 3 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
| Lerodalcibep | LIB-003 | Phase 3 Clinical | Lib Therapeutics Llc | Atherosclerosis; Hypercholesterolemia; Stroke; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
| MK-0616 | MK-0616 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Atherosclerosis; Hypercholesterolemia; Kidney Diseases; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
| AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Kidney Failure, Chronic | Details |
| CiVi-007 | CiVi-007; LNA-PCSK -9; LNA-PCSK9-GalNac | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hypercholesterolemia | Details |
| CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| ATX-304 | O-304; ATX-304; O-304X | Phase 2 Clinical | Betagenon Ab | Mitochondrial Diseases; Diabetes Mellitus, Type 2; Peripheral Arterial Disease | Details |
| MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| NNC0385-0434 | NNC0385-0434 | Phase 2 Clinical | Novo Nordisk A/S | Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Arteriosclerosis | Details |
| AZD-0780 | AZD-0780; AZD0780 | Phase 2 Clinical | Dogma Therapeutics | Dyslipidemias; Cardiovascular Diseases | Details |
| Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
| DC-371739 | JYP-0739; DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias | Details |
| Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Cardiovascular Diseases | Details | |
| ATH-04 | ATH-04; Affitope AT04A | Phase 1 Clinical | Affiris Ag | Atherosclerosis | Details |
| VERVE-101 | VERVE-101 | Phase 1 Clinical | Broad Institute, Harvard University | Plaque, Atherosclerotic; Hypercholesterolemia; Heterozygous familial hypercholesterolemia | Details |
| SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias | Details |
| SYH-2053 | SYH2053; SYH-2053 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
| VERVE-102 | VERVE-102 | Phase 1 Clinical | Verve Therapeutics Inc | Atherosclerosis; Coronary Disease; Heterozygous familial hypercholesterolemia | Details |
| SGB-3403 | SGB-3403 | Phase 1 Clinical | Suzhou Sanegene Biopharmaceuticals Ltd | Atherosclerosis; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias | Details |
| RN-0191 | RN0191 | Phase 1 Clinical | Rona Therapeutics Inc | Atherosclerosis; Hypercholesterolemia; Dyslipidemias | Details |
| RBD-7022 | RBD-7022; RBD7022 | Phase 1 Clinical | Suzhou Ribo Life Science Co Ltd | Hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
| JX-7002 | JX7002; JX-7002 | Phase 1 Clinical | Zhejiang Jingxin Pharmaceutical Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
| PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Metabolic Diseases; Inflammation | Details |
This web search service is supported by Google Inc.
A-Z
